These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 14983492

  • 1. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R, Roobol M, Schröder FH, van der Kwast TH.
    Cancer; 2004 Mar 01; 100(5):968-75. PubMed ID: 14983492
    [Abstract] [Full Text] [Related]

  • 2. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH.
    Cancer; 2005 Feb 15; 103(4):708-16. PubMed ID: 15648082
    [Abstract] [Full Text] [Related]

  • 3. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul 15; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 4. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 15; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 5. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May 15; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 6. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 15; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 7. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG.
    Cancer; 2004 Apr 01; 100(7):1397-405. PubMed ID: 15042673
    [Abstract] [Full Text] [Related]

  • 8. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 9. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH.
    Can J Urol; 2005 Jun 15; 12 Suppl 2():16-20. PubMed ID: 16018827
    [Abstract] [Full Text] [Related]

  • 10. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT, Eroglu A, Sahin A, Zorlu F, Ozen H.
    Urol Oncol; 2007 Jun 15; 25(5):376-82. PubMed ID: 17826653
    [Abstract] [Full Text] [Related]

  • 11. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H, Katayose K, Kumakawa K, Shiraiwa Y, Uchida H, Takahashi Y, Yazaki J, Yamaguchi O.
    Gan To Kagaku Ryoho; 2005 Jan 15; 32(1):57-63. PubMed ID: 15675583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
    Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA.
    Urology; 2004 Sep 15; 64(3):544-50. PubMed ID: 15351590
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb 15; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 17. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA.
    Eur Urol; 2005 Dec 15; 48(6):895-9. PubMed ID: 16125298
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 19. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 15; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 20. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
    Smith DS, Humphrey PA, Catalona WJ.
    Cancer; 1997 Nov 01; 80(9):1852-6. PubMed ID: 9351559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.